Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26699926 | 0.82 | MAPT (0.39) | EPHX2NR1H4L3MBTL1GAAMAPT | |
| SCHEMBL437844 | 0.77 | TDP1 (0.46) | L3MBTL1NPC1GAAMAPTMEN1 | |
| SCHEMBL2644738 | 0.75 | PRSS1 (0.50) | EPHX2NR1H4L3MBTL1PTPRCNPC1 | |
| SCHEMBL18736143 | 0.73 | TSHR (0.32) | EPHX2 | |
| SCHEMBL20828067 | 0.73 | EPHX2 (0.31) | EPHX2 | |
| SCHEMBL945241 | 0.72 | CA14 (0.35) | — | |
| SCHEMBL14900159 | 0.72 | STING1 (0.33) | EPHX2 | |
| SCHEMBL19500424 | 0.72 | SYK (0.46) | L3MBTL1NPC1MAPTMEN1ALDH1A1 | |
| SCHEMBL26699930 | 0.72 | BAZ2B (0.39) | NPC1MAPTSMN1; SMN2 | |
| SCHEMBL14343031 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-20110014196-A1 | Drug Transfer into Living Cells | COVALYS BIOSCIENCES AG (CH) | 2011-01-20 | — | — | US | disclosed |
| WO-2009043899-A1 | DRUG TRANSFER INTO LIVING CELLS | COVALYS BIOSCIENCES AG (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014196-A1 | Drug Transfer into Living Cells | TSPO, MPI, ABCB1 | EPHX2 2975/4885NR1H4 568/4885L3MBTL1 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.